Go Pro
→ BlackRock and Vanguard already own THIS (From Monument Traders Alliance) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
$0.95
-1.9%		$0.90
$0.60
▼
$2.28
$57.74M1.1221,773 shs10,034 shs
Mymd Pharmaceuticals, Inc. stock logo
QCLS
Mymd Pharmaceuticals
$1.71
$2.78
$1.64
▼
$8.94
$14.01M2.09218,156 shs238,318 shs
TransAct Technologies Incorporated stock logo
TACT
TransAct Technologies
$5.16
$5.17
$3.06
▼
$6.02
$53.25M1.2219,030 shs12,992 shs
VTIX
Virtuix
$1.03
$1.89
$1.02
▼
$92.74
$30.87MN/A554,522 shs368,840 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
0.00%-4.90%+10.58%+27.69%-48.87%
Mymd Pharmaceuticals, Inc. stock logo
QCLS
Mymd Pharmaceuticals
0.00%-4.47%-38.27%-57.99%+170,999,900.00%
TransAct Technologies Incorporated stock logo
TACT
TransAct Technologies
0.00%+0.39%-0.29%-0.19%+13.41%
VTIX
Virtuix
0.00%-17.60%-41.81%-69.71%+102,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
$0.95
-1.9%		$0.90
$0.60
▼
$2.28
$57.74M1.1221,773 shs10,034 shs
Mymd Pharmaceuticals, Inc. stock logo
QCLS
Mymd Pharmaceuticals
$1.71
$2.78
$1.64
▼
$8.94
$14.01M2.09218,156 shs238,318 shs
TransAct Technologies Incorporated stock logo
TACT
TransAct Technologies
$5.16
$5.17
$3.06
▼
$6.02
$53.25M1.2219,030 shs12,992 shs
VTIX
Virtuix
$1.03
$1.89
$1.02
▼
$92.74
$30.87MN/A554,522 shs368,840 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
0.00%-4.90%+10.58%+27.69%-48.87%
Mymd Pharmaceuticals, Inc. stock logo
QCLS
Mymd Pharmaceuticals
0.00%-4.47%-38.27%-57.99%+170,999,900.00%
TransAct Technologies Incorporated stock logo
TACT
TransAct Technologies
0.00%+0.39%-0.29%-0.19%+13.41%
VTIX
Virtuix
0.00%-17.60%-41.81%-69.71%+102,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
2.25
Hold$2.50162.88% Upside
Mymd Pharmaceuticals, Inc. stock logo
QCLS
Mymd Pharmaceuticals
1.00
SellN/AN/A
TransAct Technologies Incorporated stock logo
TACT
TransAct Technologies
1.50
ReduceN/AN/A
VTIX
Virtuix
2.00
Hold$11.00967.96% Upside

Current Analyst Ratings Breakdown

Latest QCLS, ICG, TACT, and VTIX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$3.00
8/21/2026
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$3.00 ➝ $2.00
8/7/2026
Mymd Pharmaceuticals, Inc. stock logo
QCLS
Mymd Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/4/2026
TransAct Technologies Incorporated stock logo
TACT
TransAct Technologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/14/2026
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
7/1/2026
VTIX
Virtuix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E-) ➝ Sell (E)
6/18/2026
VTIX
Virtuix
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$11.00
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
$31.58M1.83N/AN/A$2.30 per share0.41
Mymd Pharmaceuticals, Inc. stock logo
QCLS
Mymd Pharmaceuticals
N/AN/AN/AN/A$5.19 per shareN/A
TransAct Technologies Incorporated stock logo
TACT
TransAct Technologies
$51.48M1.03N/AN/A$3.08 per share1.68
VTIX
Virtuix
$4.25M7.26N/AN/A$0.11 per share9.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
-$6.80M-$0.12N/AN/AN/A-24.68%-5.29%-5.08%11/12/2026 (Estimated)
Mymd Pharmaceuticals, Inc. stock logo
QCLS
Mymd Pharmaceuticals
-$11.63M-$3.48N/AN/AN/AN/A-91.64%-47.48%N/A
TransAct Technologies Incorporated stock logo
TACT
TransAct Technologies
-$1.24M-$0.04N/AN/AN/A-0.75%-1.25%-0.85%11/9/2026 (Estimated)
VTIX
Virtuix
-$16.80M-$0.70N/AN/AN/AN/AN/AN/AN/A

Latest QCLS, ICG, TACT, and VTIX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/20/2026Q2 2026
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
-$0.0305-$0.18-$0.1495-$0.18$5.17 million$0.82 million
8/19/2026Q1 2027
VTIX
Virtuix
-$0.25-$0.22+$0.03-$0.22N/A$0.77 million
8/12/2026Q2 2026
Mymd Pharmaceuticals, Inc. stock logo
QCLS
Mymd Pharmaceuticals
N/A-$0.79N/A-$0.79N/AN/A
6/25/2026Q4 2026
VTIX
Virtuix
-$0.42-$0.39+$0.03-$0.39N/A$1.27 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
N/AN/AN/AN/AN/A
Mymd Pharmaceuticals, Inc. stock logo
QCLS
Mymd Pharmaceuticals
N/AN/AN/AN/AN/A
TransAct Technologies Incorporated stock logo
TACT
TransAct Technologies
N/AN/AN/AN/AN/A
VTIX
Virtuix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
N/A
16.23
15.23
Mymd Pharmaceuticals, Inc. stock logo
QCLS
Mymd Pharmaceuticals
N/A
3.29
3.29
TransAct Technologies Incorporated stock logo
TACT
TransAct Technologies
N/A
2.65
2.06
VTIX
Virtuix
0.80
0.71
0.61

Institutional Ownership

CompanyInstitutional Ownership
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
N/A
Mymd Pharmaceuticals, Inc. stock logo
QCLS
Mymd Pharmaceuticals
9.64%
TransAct Technologies Incorporated stock logo
TACT
TransAct Technologies
74.46%
VTIX
Virtuix
N/A

Insider Ownership

CompanyInsider Ownership
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
N/A
Mymd Pharmaceuticals, Inc. stock logo
QCLS
Mymd Pharmaceuticals
0.86%
TransAct Technologies Incorporated stock logo
TACT
TransAct Technologies
19.24%
VTIX
Virtuix
28.63%
CompanyEmployeesShares OutstandingFree FloatOptionable
Intchains Group Limited Unsponsored ADR stock logo
ICG
Intchains Group
13360.71 millionN/ANot Optionable
Mymd Pharmaceuticals, Inc. stock logo
QCLS
Mymd Pharmaceuticals
68.19 million8.12 millionN/A
TransAct Technologies Incorporated stock logo
TACT
TransAct Technologies
12010.32 million8.34 millionOptionable
VTIX
Virtuix
3929.97 million21.39 millionN/A

Recent News About These Companies

Virtuix Holdings Inc. to Present Recent Momentum and Omni One Expansion at H.C. Wainwright Conference
September 9, 2026  |  quiverquant.comQ
Virtuix to Highlight Accelerating Growth and Expanding Defense, Robotics and Healthcare Applications at H.C. Wainwright Conference
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358784/0/en/virtuix-to-highlight-accelerating-growth-and-expanding-defense-robotics-and-healthcare-applications-at-h-c-wainwright-conference.html
Virtuix Sells First Omni One Systems to U.S. Navy’s MWR Liberty Program
September 8, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virtuix-sells-first-omni-one-systems-to-u-s-navy-s-mwr-liberty-program-1036528487
Virtuix Sells First Omni One Enterprise Systems to U.S. Navy MWR Liberty Program in Europe
September 8, 2026  |  quiverquant.comQ
Virtuix Sells First Omni One Systems to U.S. Navy's MWR Liberty Program
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357758/0/en/virtuix-sells-first-omni-one-systems-to-u-s-navy-s-mwr-liberty-program.html
Virtuix Holdings Inc. Class A (VTIX) Gets a Buy from Maxim Group
September 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4460571/virtuix-holdings-inc-class-a-vtix-gets-a-buy-from-maxim-group/
Virtuix to Showcase AI-Enabled C-UAS Training Platform at Maneuver Warfighter Conference as Defense Programs Expand Across U.S. Military
September 2, 2026  |  quiverquant.comQ
Virtuix to Showcase AI-Enabled Counter-Drone Training System to U.S. Army Leaders at Maneuver Warfighter Conference
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355258/0/en/virtuix-to-showcase-ai-enabled-counter-drone-training-system-to-u-s-army-leaders-at-maneuver-warfighter-conference.html
Virtuix Holdings Earnings Call: Growth Meets Financial Strain
August 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/virtuix-holdings-earnings-call-growth-meets-financial-strain?utm_source=marketbeat.com&utm_medium=referral
Emerging Growth Research Issues Updated Press Release Announcing Company-Sponsored Research on Virtuix Holdings Inc.
August 27, 2026  |  accessnewswire.comA
Emerging Growth Research Reiterates Buy-Emerging Rating and $9.00 Price Target on Virtuix Following Strong Fiscal Q1 2027 Results
August 26, 2026  |  accessnewswire.comA
Virtuix targets 40% consumer unit gross margin while pursuing defense M&A with $10M-$15M annual revenue targets
August 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4635716-virtuix-targets-40-percent-consumer-unit-gross-margin-while-pursuing-defense-m-and-a-with-10m
Virtuix Holdings Inc. (VTIX) Q1 2027 Earnings Call Transcript
August 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4938780-virtuix-holdings-inc-vtix-q1-2027-earnings-call-transcript
Virtuix Highlights Strong Omni One Order Growth
August 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/virtuix-highlights-strong-omni-one-order-growth?utm_source=marketbeat.com&utm_medium=referral
Virtuix Holdings (VTIX) Stock Rises on Q1 2027 Earnings
August 19, 2026  |  quiverquant.comQ
Virtuix Reports First Quarter Fiscal Year 2027 Results as Omni One Orders Increase 150% Following Meta Launch
August 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/19/3348027/0/en/virtuix-reports-first-quarter-fiscal-year-2027-results-as-omni-one-orders-increase-150-following-meta-launch.html
New to The Street Airs This Weekend Across Bloomberg Television U.S., Latin America and MENA
August 17, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/40371/new-to-the-street-airs-this-weekend-across-bloomberg-television-us-latin-america-and-mena/
Short Interest in Virtuix Holdings Inc. (NASDAQ:VTIX) Rises By 78.1%
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-virtuix-holdings-inc-nasdaqvtix-rises-by-781-2026-08-17/
Virtuix (NASDAQ:VTIX) Stock Rating Upgraded by Wall Street Zen
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/virtuix-nasdaqvtix-stock-rating-upgraded-by-wall-street-zen-2026-08-15/
Virtuix to Highlight Accelerating Consumer Growth and Expansion Across Defense, Robotics, and Healthcare at Sidoti Investor Conference
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344598/0/en/virtuix-to-highlight-accelerating-consumer-growth-and-expansion-across-defense-robotics-and-healthcare-at-sidoti-investor-conference.html
Virtuix Holdings Inc.: Virtuix Reschedules First Quarter Fiscal 2027 Results Following Recent Transition to New Independent Accounting Firm
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69299546-virtuix-holdings-inc-virtuix-reschedules-first-quarter-fiscal-2027-results-following-recent-transition-to-new-independent-accounting-firm-399.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Shoppers browse folded and hanging clothing in a retail apparel store with shelves and racks displayed.
3 Retail Stocks to Watch After a Big Consumer Earnings Week
By Dan Schmidt | August 29, 2026
Amgen logo displayed on a glass panel in a laboratory setting with microscopes and sample vials.
Amgen Drops 10% on a Trial It Didn't Even Run
By Chris Markoch | September 11, 2026
Intchains Group stock logo

Intchains Group NASDAQ:ICG

$0.95 -0.02 (-1.95%)
Closing price 09/11/2026 03:49 PM Eastern
Extended Trading
$0.96 +0.00 (+0.42%)
As of 07:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intchains Group Limited designs and sells application-specific integrated circuit chips for blockchain applications in the People's Republic of China. The company also offers ancillary software, hardware, and other products. It serves distributors. Intchains Group Limited was founded in 2017 and is based in Pudong, China.

Mymd Pharmaceuticals stock logo

Mymd Pharmaceuticals NASDAQ:QCLS

$1.71 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$1.56 -0.16 (-9.06%)
As of 07:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

TransAct Technologies stock logo

TransAct Technologies NASDAQ:TACT

$5.16 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$5.17 +0.01 (+0.19%)
As of 07:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TransAct Technologies Incorporated designs, develops, and markets transaction-based and specialty printers and terminals in the United States and internationally. It offers thermal printers and terminals to generate labels, coupons, and transaction records, such as receipts, tickets, and other documents. The company also provides consumable products, including POS receipt paper, inkjet cartridges, ribbons, and other printing supplies, as well as replacement parts and accessories; and maintenance and repair services. In addition, it offers EPICENTRAL print system, a software solution that enables casino operators to create promotional coupons and marketing messages, and print them at the slot machine; and technical support services, as well as spare parts and accessories. Further, the company provides BOHA! terminal that combines hardware and software components in a device that includes an operating system, touchscreen, and one or two thermal print mechanisms. It markets its products under the TransAct, BOHA!, AccuDate, Ithaca, and EPICENTRAL brands for food service technology, point of sale automation, and casino and gaming markets. The company sells its products to original equipment manufacturers, value-added resellers, and distributors, as well as directly to end-users through its Webstore transactsupplies.com. TransAct Technologies Incorporated was incorporated in 1996 and is headquartered in Hamden, Connecticut.

Virtuix NASDAQ:VTIX

$1.03 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$1.02 -0.01 (-0.58%)
As of 07:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Virtuix pioneers movement in AI-generated worlds, real or imaginary. We are the creator of “Omni,” the premier brand of omni-directional treadmills that let players walk and run in 360 degrees inside virtual reality (“VR”) games, digital twins, and other applications, positioning us at the intersection of gaming, fitness and enterprise VR. To date, we’ve brought three products to market and generated over $20 million in sales. We target a gross margin of 40% on our hardware products, supplemented by recurring revenues from software sales and subscriptions. We increased quarterly revenue 4x from the first quarter to the fourth quarter of fiscal year 2025 (primarily resulting from recognizing Omni One preorder sales). Products Our “Omni” line of omni-directional treadmills consists of various products that target a variety of industries: Omni Pro, the original Omni, is our commercial-grade treadmill launched in 2016 for enterprise use in arcades, VR centers, corporations, and research institutions. We have shipped over 4,000 Omni Pro units to more than 45 countries worldwide. Following the launch of Omni One in 2024, we stopped production and sales of Omni Pro. Omni Arena launched in 2019 as a turnkey attraction for the out-of-home entertainment industry. The attraction comprises four Omni Pro treadmills for multiplayer gaming and features weekly esports prize contests. We’ve installed 80 Omni Arena systems at entertainment centers in the United States (“U.S.”) and built a player base of over 500,000 players who signed up with an email address to play. Several players have paid to play the attraction more than 300 times. Following our shift in research and development (“R&D”) and marketing efforts to Omni One, we stopped producing and selling new Omni Arena systems in 2025, but we continue to service existing customers and earn recurring revenues through the sale of Omni Care maintenance services, Omniverse game credits, and replacement parts. We also facilitate and earn profits on secondary sales of Omni Arena systems. Omni One is our latest product and our most advanced treadmill yet, supporting full freedom of movement including crouching, kneeling, and jumping. It’s a compact device that is easy to assemble and disassemble, and it can be moved around using its wheels. We sell Omni One in three different versions: the complete Omni One system, Omni One Core, and Omni One Enterprise. We officially launched Omni One in September 2024, and by September 2025, we shipped the first 1,800 units to customers, resulting in revenues of over $4,000,000. In addition to hardware sales, we earn recurring revenues from the sale of Omni One games and from monthly subscriptions to Omni Online (priced at $14/month), Omni One’s service that allows customers to play online multiplayer games. During checkout, approximately 50% of Omni One customers purchase an annual subscription to Omni Online. Virtual Terrain Walk (“VTW”) is our multi-user system for next-generation mission planning in the defense industry. VTW lets soldiers move physically in 360 degrees inside geo-specific virtual environments, without boundaries, for ground combat planning and leader rehearsals. The geo-specific virtual environments are digital twins of real-world environments, created by converting drone and other camera footage into photorealistic 3D scenes via Gaussian splatting and other AI-driven 3D reconstruction techniques. VTW is currently in development. YokoWERX, an innovation cell of the U.S. Air Force, purchased two prototype stations for experimentation purposes. We aim to present a proof-of-concept of VTW to potential customers by calendar year-end 2025, although we expect that meaningful sales of VTW in the defense sector may not materialize until fiscal year 2027 at the earliest. Despite the long sales cycle for penetrating the defense market, we believe that VTW will retain a strong competitive moat because of our expansive omni-directional treadmill patent portfolio, our position as a U.S. company, and the inherent barriers to entry for defense applications that competitors will face, including multi-year procurement cycles and high switching costs. Our principal executive offices are located in Austin, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas